Copyright © 2016

Aridis Pharmaceuticals, Inc.

5941 Optical Court, San Jose, CA 95138

Phone: 408-385-1742

Site Map

Privacy Policy

Financial Conflict of Interest Policy

Back to top

Previous page

Clinical Advisory Board

Jean Chastre, M.D.

Dr. Chastre, Consulting Professor in the Medical ICU and former director of the same ICU at Institut de Cardiologie, Groupe Hospitalier Pitié-Salpêtrière in Paris, France, also served as a member of the Clinical Advisory Board at Kenta Biotech AG (formerly Kenta Biotech Ltd.). He is a recognized expert in the performance of clinical outcomes research in the ICU setting and his clinical research focus has been the understanding, diagnosis and treatment of nosocomial infections and the improved care of mechanically ventilated patients. He is also a professor of medicine at Paris 6 University School of Medicine, Faculté de Médecine Pitié-Salpêtrière, France, and has published more than 170 peer-reviewed papers and authored or co-authored 18 book chapters. He earned his fellowship in cardiology and critical care and is licensed and board certified in cardiology with a subspecialty in critical care.

Marin Kollef, M.D.

Dr. Kollef is the director of the medical intensive care unit and respiratory care services at Barnes-Jewish Hospital in St. Louis, Missouri. He is also a professor of medicine at Washington University, School of Medicine, and has lectured on numerous critical care topics such as fungal infection, VAP, antibiotic resistance and antibiotic therapy optimization. He serves on the editorial boards of numerous medical journals, such as Respiratory Care, Critical Care and Journal of Surgical Infections. He is the recipient of various honors and awards, including selection to “Best Doctors in America,” central region and Barnes-Jewish Hospital team awards for quality improvement for programs directed to VAP prevention, bloodstream infection prevention and the “Surviving Sepsis Initiative.” His awards for military service with the First Infantry Division during operation Desert Storm include Bronze Star, Meritorious Service Medal and Combat Medical Badge in support of combat operations. He is also a member of multiple organizations in his field and chair for the Global Anti-Infectives Leadership Academy.

Bruno Francois, M.D.

Dr. Francois, a specialist in intensive care medicine and anesthesiology, heads the Limoges Clinical Investigation Center with a specific focus on infectious diseases in critically ill patients at the University Hospital of Limoges, France. He has participated in several advisory boards for Sepsis and VAP multinational trials, independent clinical evaluation committees and adjudication committees. He is also the author of multiple publications and a reviewer for medical journals focused on infectious disease in the ICU.  He is currently investigating the role of bacterial resistance mechanisms and integrons during Sepsis with the Marie-Cécile Ploy Inserm research team from Limoges, France. He created the CRICS network dedicated to clinical research in Sepsis trials in 2007 and is now co-leading the French TRIGGERSEP research network (F-CRIN certification within ECRIN), which integrates all research activities in Sepsis from basic science to clinical trials. He is also coordinating the COMBACTE consortium within the IMI framework and leading the SAATELLITE trial in collaboration with Medimmune since 2012.

Michael Niederman, M.D.

Dr. Niederman is Professor of Medicine and Vice-Chairman of the Department of Medicine at the SUNY Stony Brook School of Medicine. A practicing pulmonologist for 30 years and a leading expert in hospital-acquired pneumonia. He has authored over 300 peer-reviewed or review articles, is co-editor of the first and second editions of the textbook, Respiratory Infections: A Scientific Basis for Management and editor-in-chief of Clinical Pulmonary Medicine. He obtained his degree from Boston University School of Medicine, performed residency at Northwestern University Medical School and fellowship in Pulmonary and Critical Care at Yale University School of Medicine. Dr. Niederman is a Fellow of, and active member of The American College of Chest Physicians, The American College of Physicians and The American Thoracic Society.

Richard B. Moss, M.D.

Dr. Moss is professor of Pediatrics at Stanford University School of medicine and chief, pediatric pulmonology and allergy with over 150 scientific publications. He is the chair of the protocol review committee for the Cystic Fibrosis Therapeutics Development Network (TDN). Dr. Moss’s honors include The Best Doctors in America, America’s Top Pediatricians - Pulmonology and Professional of the Year by the Cystic Fibrosis Foundation (CFF). His research involves the immunoregulation of inflammation in cystic fibrosis and he has been involved in numerous CF clinical trials. One of his research interests is aerosol gene therapy for in vivo correction of genetic lung disease and new treatments for CF complications such as diabetes and osteoporosis.

Alan H Cohen, M.D., FAAP, FCCP

Dr Cohen is a board certified Pediatric Pulmonologist and currently the Vice President, Clinical Development and Medical Affairs at Intermune. He also holds an appointment as adjunct clinical faculty at Stanford University School of Medicine – in the Dept of Pediatric Pulmonology and Allergy. He is the author of over 100 peer reviewed articles, abstracts, platform presentations and book chapters in his areas of interest and expertise, including Cystic Fibrosis, Lung Transplantation, Infectious Disease and respiratory pathogens. He was formerly the Senior Director of Medical Affairs at Medimmune. He has held faculty appointments in a number of academic centers including the Johns Hopkins School of Medicine, Morehouse School of Medicine, Washington University School of Medicine, as well as the University of Colorado / National Jewish Center for Immunology and Respiratory Diseases.


Breakthrough Therapies for

Antibiotic Resistant Infections

Aridis Home